Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Axel Finckh

Showing results (191-200 of 225) with videos related to

Pageof 23
Sort By:
RMD Open|February 5, 2019
EULAR 'points to consider' for the conduction of workforce requirement studies in rheumatologyChristian Dejaco, Polina Putrik, Julia Unger, et al.
Clinical Rheumatology|October 24, 2014
An Internet-based technique for the identification of persons with symptoms of inflammatory polyarthritis of less than 12 weeksMatthew H Liang, Maura C M Couto, Cátia C M Duarte, et al.
RMD Open|November 28, 2025
Identification of individuals at high risk of developing rheumatoid arthritis: a balanced random forest model in a cohort of 1544 first-degree relativesRomain Aymon, Céline Lamacchia, Benoit Thomas P Gilbert, et al.
RMD Open|November 18, 2021
Analysing and reporting of observational data: a systematic review informing the EULAR points to consider when analysing and reporting comparative effectiveness research with observational data in rheumatologyKim Lauper, Joanna Kedra, Maarten de Wit, et al.
Annals of the Rheumatic Diseases|January 21, 2022
EULAR points to consider when analysing and reporting comparative effectiveness research using observational data in rheumatologyDelphine Sophie Courvoisier, Kim Lauper, Joanna Kedra, et al.
Clinical Rheumatology|January 23, 2017
The prevalence of anticitrullinated protein antibodies increases with age in healthy individuals at risk for rheumatoid arthritisD Alpizar-Rodriguez, Laure Brulhart, Ruediger B Mueller, et al.
Annals of the Rheumatic Diseases|March 23, 2019
2018 EULAR recommendations for a core data set to support observational research and clinical care in giant cell arteritisLisa Ehlers, Johan Askling, Hans Wj Bijlsma, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|April 6, 2026
Machine Learning to Predict Remission Between Six and 24 Months in Rheumatoid Arthritis: Insights from the JAK-pot CollaborationZubeyir Salis, Denis Mongin, Denis Choquette, et al.
RMD Open|February 5, 2019
Workforce requirements in rheumatology: a systematic literature review informing the development of a workforce prediction risk of bias tool and the EULAR points to considerJulia Unger, Polina Putrik, Frank Buttgereit, et al.
Seminars in Arthritis and Rheumatism|February 21, 2026
Evolution of Janus Kinase inhibitors (JAKi) prescriptions since 2015 in an international collaboration of rheumatoid arthritis registers (the 'JAK-pot' study): effect of regulatory warningsDenis Mongin, Romain Aymon, Denis Choquette, et al.
Pageof 23

Showing results (191-200 of 225) with videos related to

Sort By:
Pageof 23
RMD Open|February 5, 2019
EULAR 'points to consider' for the conduction of workforce requirement studies in rheumatologyChristian Dejaco, Polina Putrik, Julia Unger, et al.
Clinical Rheumatology|October 24, 2014
An Internet-based technique for the identification of persons with symptoms of inflammatory polyarthritis of less than 12 weeksMatthew H Liang, Maura C M Couto, Cátia C M Duarte, et al.
RMD Open|November 28, 2025
Identification of individuals at high risk of developing rheumatoid arthritis: a balanced random forest model in a cohort of 1544 first-degree relativesRomain Aymon, Céline Lamacchia, Benoit Thomas P Gilbert, et al.
RMD Open|November 18, 2021
Analysing and reporting of observational data: a systematic review informing the EULAR points to consider when analysing and reporting comparative effectiveness research with observational data in rheumatologyKim Lauper, Joanna Kedra, Maarten de Wit, et al.
Annals of the Rheumatic Diseases|January 21, 2022
EULAR points to consider when analysing and reporting comparative effectiveness research using observational data in rheumatologyDelphine Sophie Courvoisier, Kim Lauper, Joanna Kedra, et al.
Clinical Rheumatology|January 23, 2017
The prevalence of anticitrullinated protein antibodies increases with age in healthy individuals at risk for rheumatoid arthritisD Alpizar-Rodriguez, Laure Brulhart, Ruediger B Mueller, et al.
Annals of the Rheumatic Diseases|March 23, 2019
2018 EULAR recommendations for a core data set to support observational research and clinical care in giant cell arteritisLisa Ehlers, Johan Askling, Hans Wj Bijlsma, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|April 6, 2026
Machine Learning to Predict Remission Between Six and 24 Months in Rheumatoid Arthritis: Insights from the JAK-pot CollaborationZubeyir Salis, Denis Mongin, Denis Choquette, et al.
RMD Open|February 5, 2019
Workforce requirements in rheumatology: a systematic literature review informing the development of a workforce prediction risk of bias tool and the EULAR points to considerJulia Unger, Polina Putrik, Frank Buttgereit, et al.
Seminars in Arthritis and Rheumatism|February 21, 2026
Evolution of Janus Kinase inhibitors (JAKi) prescriptions since 2015 in an international collaboration of rheumatoid arthritis registers (the 'JAK-pot' study): effect of regulatory warningsDenis Mongin, Romain Aymon, Denis Choquette, et al.
Pageof 23